Pharming Technologies has successfully acquired approximately 87.7 percent of Abliva's shares, solidifying its position in the biotechnology market while waiving the initial acceptance level condition for completion.

Target Information

Abliva, a prominent player in the biotechnology sector, has received a cash acquisition offer from Pharming Technologies. As of February 7, 2025, shareholders holding approximately 1,413,841,472 shares, representing 87.7 percent of Abliva's total shares, accepted the offer. This substantial acceptance indicates a strong confidence among Abliva's investors regarding the strategic move.

Industry Overview in Sweden

Sweden's biotechnology sector has been rapidly evolving, showcasing significant advancements in research and development. The country is recognized for its robust innovation ecosystem, supported by strong governmental initiatives and a favorable funding landscape. This environment attracts global investors and encourages local startups to thrive, particularly in fields like pharmaceuticals and medical devices.

The Swedish market is characterized by high-quality research institutions and a collaborative atmosphere among academia, industry, and government agencies